Slides on Key Decisions in HIV Care: Assessing Candidacy for Long-Acting ART

Learn the data on which patient factors may predict failure to LA CAB + RPV and who is and who is not a good candidate for this new treatment option
Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP
Format: Microsoft PowerPoint (.ppt)
File Size: 462 KB
Released: December 1, 2021

Acknowledgements

Educational grant provided by:
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Related Content

Get expert updates on ART safety and tolerability from fall conferences, from Clinical Care Options (CCO)

Eric K. Farmer, PharmD, BCPS, AAHIVP Darcy Wooten, MD Physicians: maximum of 0.5 AMA PRA Category 1 Credits Registered Nurses: 0.5 Nursing contact hours Pharmacists: 0.5 contact hours (0.05 CEUs) Released: January 24, 2023 Expired: January 23, 2024

European pioneers discuss the latest data and guideline recommendations for implementing LA ART into practice, from Clinical Care Options (CCO)

Celia Jonsson-Oldenbuettel, MD, PhD
Program Director
person default Tom Stephane De Wit, MD, PhD Eric Florence, MD, PhD Mireia SantaCreu Guerrero, MSN person default Laurence Slama, MD, PhD
Physicians: maximum of 1.5 AMA PRA Category 1 Credits Released: January 20, 2023 Expired: January 19, 2024

Dr Eric Florence discusses clinic adaptations to promote successful integration of long-acting injectables for HIV in this commentary from Clinical Care Options (CCO)

Eric Florence, MD, PhD Released: January 17, 2023

Slides on HIV ART management in complex clinical situations, including extensive previous treatment, from Clinical Care Options (CCO)

Joseph J. Eron, Jr., MD
Program Director
Jeffrey Kwong, DNP, MPH, AGPCNP-BC, ACRN, FAANP, FAAN, AAHIVS
Program Director
Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP
Program Director
Released: January 11, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings